Mazdutide Shows Significant Weight Loss in Phase 3 Trial
Key Summary Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity. 84.3%
Read MoreKey Summary Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity. 84.3%
Read MoreIn a recent study published in JAMA Network Open, researchers investigated whether prenatal exposure to maternal Severe Acute Respiratory Syndrome
Read More